Perbak Capital Partners LLP Raises Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Perbak Capital Partners LLP boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 280.8% in the third quarter, Holdings Channel.com reports. The firm owned 14,157 shares of the medical equipment provider’s stock after buying an additional 10,439 shares during the quarter. Perbak Capital Partners LLP’s holdings in Zimmer Biomet were worth $1,394,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brown Brothers Harriman & Co. grew its position in shares of Zimmer Biomet by 23.5% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,200 shares of the medical equipment provider’s stock worth $217,000 after buying an additional 419 shares during the period. Dodge & Cox lifted its position in Zimmer Biomet by 5.1% during the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock valued at $2,286,793,000 after acquiring an additional 1,118,710 shares during the period. Glenmede Investment Management LP boosted its stake in Zimmer Biomet by 9.7% during the third quarter. Glenmede Investment Management LP now owns 10,432 shares of the medical equipment provider’s stock worth $1,028,000 after acquiring an additional 926 shares in the last quarter. Pathstone Holdings LLC grew its holdings in Zimmer Biomet by 19.0% in the third quarter. Pathstone Holdings LLC now owns 45,839 shares of the medical equipment provider’s stock worth $4,515,000 after purchasing an additional 7,333 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Zimmer Biomet by 21.0% during the third quarter. Marshall Wace LLP now owns 301,970 shares of the medical equipment provider’s stock valued at $29,744,000 after purchasing an additional 52,487 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $93.24 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44. The company has a market capitalization of $18.24 billion, a P/E ratio of 26.34, a price-to-earnings-growth ratio of 1.89 and a beta of 0.58. The firm has a 50 day moving average of $92.40 and a 200 day moving average of $95.28. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. During the same period in the prior year, the firm posted $2.31 EPS. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 27.12%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ZBH shares. Sanford C. Bernstein boosted their price target on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. William Blair initiated coverage on Zimmer Biomet in a research note on Friday, February 20th. They set a “market perform” rating for the company. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. Finally, Citigroup reissued a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.